Harvett,
Once again you have missed the point.
You accuse Graham Kelly of having improbable timelines, but you (wilfully?) ignore the fact that his timelines were based on starting clinical trials in Australia, where an IND is not required.
The new regime at Kazia went another route, which is their prerogative. The mistake they made, in my opinion, was that in their zeal to not do a Kelly, they stopped communicating with shareholders.
Expand
